PHARMA
& BIOTECH
Neurology is becoming an increasingly important field for biopharmaceutical innovation. Progress in monoclonal antibodies, recombinant proteins and other biologics is opening new therapeutic possibilities for neurodegenerative diseases, rare neurological disorders and immune-mediated conditions. As more of these therapies advance from clinical development toward commercial supply, manufacturers need production platforms that can scale reliably while meeting stringent GMP requirements.
Bringing these therapies to market is not only a question of developing the right molecule. It also depends on robust upstream and downstream processes, sterile production environments, dependable clean utilities, automation, qualification and the flexibility to adapt as products and volumes evolve. In this context, manufacturing infrastructure is becoming a strategic part of how neurological innovation reaches patients.
A Market Gaining Momentum
The rise of neurological biologics reflects a broader shift across the pharmaceutical industry. Recent market analyses estimate that the global monoclonal antibody market could increase from around USD 324 billion in 2026 to nearly USD 600 billion by 2031, supported by growing use in oncology, autoimmune diseases and neurological indications.
The neurological therapeutics market is also expected to expand significantly, with projections placing its global value above USD 150 billion by 2031. Growth is being supported by rising disease prevalence, ageing populations and the arrival of disease-modifying therapies. Analysts point to biologics, gene therapies and precision medicines as important drivers of the next phase of CNS treatment.
For manufacturing facilities, this shift translates into a clear set of priorities:
- Flexible and scalable production capacity
- Advanced purification technologies
- Sterile formulation and processing capabilities
- High-performance clean utility systems
- Digitalisation, automation and data integrity
- Accelerated GMP readiness and regulatory compliance
As neurological pipelines diversify and product requirements become more demanding, manufacturing environments need to evolve with them.
Alzheimer’s Disease: A New Chapter for Neurological Biologics
Alzheimer’s disease illustrates how quickly the manufacturing landscape in neurology is changing. The arrival of anti-amyloid monoclonal antibodies has moved large-molecule biologics firmly into a therapeutic area that was historically dominated by small-molecule treatments.
Industry forecasts indicate continued double-digit growth for anti-amyloid antibody therapies over the coming decade. Wider access to disease-modifying treatments, better diagnosis and sustained investment in neuroscience are expected to increase demand, with several market studies anticipating further manufacturing expansion as these therapies reach broader patient populations.
Scaling these products calls for tightly controlled biopharmaceutical operations, including:
- Mammalian cell culture systems
- Chromatography and purification platforms
- Ultrafiltration and concentration technologies
- Sterile formulation operations
- Water for Injection (WFI) and clean utility systems
- Automated process monitoring and batch traceability
The result is a need for facilities that deliver efficiency without compromising product quality, process control or regulatory compliance.
From Cell Culture to Final Formulation
Production Systems for Monoclonal Antibodies and Therapeutic Proteins
Producing modern neurological biologics involves a closely connected chain of sophisticated processes, from upstream production through purification and final formulation.
Monoclonal antibodies and recombinant proteins depend on stable, tightly controlled production conditions that protect sensitive biological processes and ensure consistent product quality.
Boccard supports therapeutic protein and biologics manufacturing with expertise across:
- Mammalian cell culture
- Fermentation technologies
- Buffer preparation
- Process skids and modular units
- Automation and supervisory systems
- Utility integration
- Qualification and commissioning
This experience covers both large commercial facilities and smaller, flexible production platforms designed for evolving biologics portfolios and changing capacity needs.
Purification and Downstream Processing
Downstream processing is a decisive stage in biologics manufacturing, with a direct impact on product purity, consistency and overall process performance.
Meeting the purity requirements of therapeutic proteins and antibody-based products typically relies on a combination of advanced downstream technologies, including:
- Chromatography
- Ultrafiltration
- Nanofiltration
- Viral inactivation
- Sterile transfer systems
- Formulation and buffer preparation
Boccard’s project experience includes the integration of large-scale purification systems, protein recovery operations and sterile processing environments for demanding biopharmaceutical applications.
Over several decades, Boccard has contributed to biopharmaceutical projects across international markets, including facilities and systems for therapeutic proteins, plasma-derived therapies, recombinant proteins, vaccines and sterile manufacturing.
This project experience includes:
- Large-scale protein purification facilities
- Biopharmaceutical production environments
- Recombinant protein manufacturing systems
- Vaccine production units
- Therapeutic protein process platforms
- High-capacity purification and formulation installations
- GMP process equipment and automation systems
The know-how developed across these applications can be applied to manufacturers working on both established and next-generation neurological biologics.
Clean Utilities: A Critical Foundation for Reliable Biopharmaceutical Production
Reliable biologics production depends on utility systems that perform consistently behind the process itself.
Boccard designs and integrates systems for:
- Purified Water (PW)
- Water for Injection (WFI)
- Clean Steam
- CIP and SIP systems
- Process gases
- Pharmaceutical utility distribution networks
Together, these systems help maintain sterility, reproducibility and GMP compliance throughout the manufacturing lifecycle. Boccard has delivered pharmaceutical water and clean utility projects internationally, supporting sterile production environments and biologics facilities with reliable utility infrastructure.
Flexible Support for Greenfield, Expansion and Brownfield Projects
No two manufacturing projects start from the same point. Capacity needs, existing infrastructure, investment priorities and implementation constraints all shape the right delivery model.
Some manufacturers need focused support for a single process package, utility system or purification unit. Others need an integrated partner to coordinate engineering, procurement, construction, automation, installation and qualification across the full project lifecycle.
Boccard can support:
- Greenfield biologics facilities
- Capacity expansion projects
- Brownfield upgrades
- Utility modernization programs
- Process intensification initiatives
- Sterile manufacturing environments
Depending on the project scope, Boccard can deliver individual process packages or take responsibility for an integrated installation from engineering through qualification.
Preparing Manufacturing for the Next Era of Neurology
The next generation of neurological treatments is expected to draw increasingly on biologics, advanced proteins, antibodies and precision medicines. Industry reports identify the convergence of biologics, gene therapies and new CNS treatment approaches as an important trend that will shape
As pipelines grow and divesify, manufacturers will need facilities that can handle more complex products while preserving quality, compliance and operational efficiency.
Whether the product is a monoclonal antibody, recombinant protein, plasma-derived therapy or another advanced biologic, successful scale-up depends on how well process engineering, purification, sterile processing, clean utilities, automation and GMP qualification work together as one manufacturing system.
Boccard brings these disciplines together to help manufacturers turn scientific progress into robust industrial production, with flexible and scalable biopharmaceutical solutions designed for today’s therapies and the products still to come.
Engineering Expertise Built on Decades of Biopharmaceutical Projects
What differentiates Boccard is not only its ability to supply equipment, but its capacity to combine process engineering, mechanical design, automation, clean utilities and project execution within one organization.
Over the years, Boccard has contributed to a wide range of pharmaceutical and biotechnology projects across international markets, supporting manufacturers from early process development through commercial-scale production. This experience spans biologics, therapeutic proteins, recombinant products, plasma-derived therapies, vaccines and sterile manufacturing environments.
With dedicated teams of process engineers, mechanical designers, automation specialists, qualification experts and manufacturing personnel, Boccard can manage complex multidisciplinary projects while maintaining full control over quality, performance and compliance requirements.
Our portfolio includes numerous custom-engineered installations designed around each client’s process, facility constraints and growth strategy. From cell culture and fermentation systems to purification platforms, clean utilities and fully integrated production facilities, every project contributes to a growing body of engineering knowledge that can be applied to new manufacturing challenges.
This combination of in-house expertise, practical project experience and exposure to a broad range of manufacturing technologies enables Boccard to support both established pharmaceutical manufacturers and emerging biotechnology companies as they scale from innovation to industrial production.
Want to learn more about our solutions for
Pharma & Biotech?
You have a project ?
Our Customers
They trust us
